Core Viewpoint - Morgan Stanley's report indicates that Highway Electronics (01415) underperformed the Hang Seng Index in Q4 last year due to market concerns over rising memory prices potentially weakening iPhone demand [1] Group 1: Earnings Forecast - The bank raised its earnings forecast for 2025 to 2027 by 3% to 9%, expecting a year-on-year profit growth of 23% and 26% for 2026 and 2027 respectively [1] Group 2: Market Reaction - The bank believes the market reaction has been excessive, as its research shows resilience in this year's orders, with an expected year-on-year growth of 8% in electronic manufacturing services shipments for the first half of the year [1] Group 3: Product Line Impact - The adjusted iPhone product line in the second half of this year is expected to benefit Highway Electronics, particularly due to its higher business share in the Pro and Pro Max models, along with continuous market share expansion [1] Group 4: Market Share Growth - The bank anticipates that the company will gain additional market share in the main rear camera module sector by 2027 [1]

Core Viewpoint - The company, Guanghong Technology, is a professional EMS (Electronic Manufacturing Services) provider and does not directly engage in PCB (Printed Circuit Board) manufacturing. PCB is an essential raw material for the company's operations, serving as a foundational component for electronic products [1]. Group 1 - The company specializes in EMS, indicating a focus on providing manufacturing services rather than producing PCBs directly [1]. - PCB is highlighted as a crucial raw material for the company's business, emphasizing its importance in the electronic manufacturing process [1]. - The integration of PCB and various electronic components through SMT (Surface Mount Technology) is identified as a key aspect of the company's operations [1].

Financial Data and Key Metrics Changes - Net sales for Q1 fiscal 2026 were $366 million, a 2% decline compared to Q1 fiscal 2025 [5][10] - Gross margin rate improved to 7.9%, a 160 basis point increase from 6.3% in the same period last year [10] - Adjusted income for Q1 was $17.5 million, or 4.8% of net sales, compared to $12.6 million, or 3.4% of net sales last year [11][12] - Adjusted net income was $12.3 million, or $0.49 per diluted share, up from $5.5 million, or $0.22 per diluted share last year [12][13] - Cash and cash equivalents at the end of Q1 were $75.7 million, with cash generated from operations at $8.1 million [13][15] Business Line Data and Key Metrics Changes - Medical sales were $102 million, up 13% year-over-year, accounting for 28% of total revenue [5][6] - Automotive sales were $164 million, down 10% year-over-year, representing 45% of total sales [7] - Industrial sales totaled $100 million, a 1% decrease compared to Q1 last year, making up 27% of total sales [7][8] Market Data and Key Metrics Changes - Medical sales growth was driven by strong performance in North America, Asia, and Europe [5][6] - Automotive sales decline was primarily due to lower sales in North America and Asia, partially offset by growth in Europe [7] - Industrial business saw a decline in North America due to softening demand for HVAC, while Asia reported strong sales growth [8] Company Strategy and Development Direction - The company aims to expand its capabilities in the medical sector, focusing on higher-level assemblies and finished medical devices [6][18] - A tuck-in acquisition strategy is being pursued to add new end markets and manufacturing capabilities [18] - The company is committed to returning to profitable growth, particularly in the medical space, while managing costs and improving margins [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to profitable top-line growth next year and reiterated guidance for fiscal 2026 [4][16] - The company is monitoring the evolving global tariff landscape and expects to recover tariff costs by passing them on to customers [8][9] - Management highlighted the importance of maintaining a strong balance sheet while preparing for growth [43][44] Other Important Information - Cash conversion days improved to 83 days, representing the lowest level in over three years [13][14] - Capital expenditures in Q1 were $10.6 million, primarily for leasehold improvements and the new facility in Indianapolis [15][16] - The company has $14.8 million remaining on its share repurchase program [15] Q&A Session Summary Question: Will working capital increase as top-line growth resumes? - Management does not expect a significant increase in working capital as they have improved inventory management [21][22] Question: Is the current cash conversion days level stable? - Management aims for cash conversion days to remain in the low 80s as the business grows [23] Question: What are the expectations for EBITDA margins? - Management does not expect a deterioration in EBITDA margins and anticipates improvements as growth resumes [24] Question: What is the focus for potential acquisitions in the medical segment? - The company is exploring acquisitions in the medical CMO space, focusing on new technologies and geographies [28] Question: How does the pipeline of medical projects look for revenue growth? - The company has a strong pipeline of medical projects and expects to close several as the year progresses [37][38] Question: What is the outlook for the automotive segment? - Management anticipates continued pressure in the automotive market but remains strategically focused on high-visibility revenue [41] Question: How is the company balancing organic growth and potential acquisitions? - Management is focused on disciplined capital allocation and will consider acquisitions that enhance their CMO strategy [43][44] Question: What impact does accelerated depreciation have on the company? - Accelerated depreciation is beneficial, particularly regarding interest expense deductions [46]

Financial Data and Key Metrics Changes - Net sales for Q3 totaled $375 million, representing a 10% decline year over year when excluding the divested AT and M business [8][13] - Gross margin rate in Q3 was 7.2%, a 70 basis point decline compared to 7.9% in the same period last year, primarily due to a non-recurring consignment inventory sale [13][14] - Adjusted net income for Q3 was $6.8 million or $0.27 per diluted share, down from $9.8 million or $0.39 per diluted share in the same quarter last year [17] Business Line Data and Key Metrics Changes - Medical segment net sales were $115 million, up 2% year over year, driven by non-recurring consignment inventory sales [8][9] - Automotive segment net sales were $173 million, a 14% decrease year over year, representing 46% of total company sales [10] - Industrial segment net sales were $86 million, down 15% year over year, representing 23% of total company sales [11] Market Data and Key Metrics Changes - Sales in the Medical market increased, while the Automotive and Industrial markets experienced declines [8][10][11] - The automotive business is heavily concentrated in North America and China, with growth noted in Europe due to a new electronic braking platform [10] Company Strategy and Development Direction - The company is focusing on expanding its presence in the medical contract manufacturing organization (CMO) space, with a new manufacturing facility in Indianapolis [6][9] - The strategy includes utilizing cash generated from EMS operations to invest in the medical CMO, with expectations for organic revenue growth over time [6][7] - The company aims to improve its global capacity utilization by closing the Tampa facility and streamlining operations [25] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about returning to growth through emerging medical technologies and high-level assemblies [25] - The current tariff environment presents uncertainty, impacting the business and customer demand [23][24] - Management is closely monitoring customer demand and market conditions to navigate the unpredictable environment [23][40] Other Important Information - Cash and cash equivalents at the end of Q3 were $51.4 million, with cash flow from operating activities at $30.9 million [17][19] - The company has $19.3 million remaining on its share repurchase program, having repurchased $3 million worth of shares in Q3 [20] Q&A Session Summary Question: Details about the new facility in Indianapolis - The new facility provides more space for growth in the medical CMO and is leased to minimize upfront costs [28][30] Question: Impact of the existing facility's sale - It is too early to determine the potential value of the existing facility, with a transition period of two to three years expected [32] Question: Trends in open orders or backlog - The medical vertical saw the greatest increase in open orders, followed by industrial and automotive [34] Question: Orders pulled into March due to tariffs - Management is uncertain if orders were pulled forward due to tariffs but is monitoring customer feedback [38] Question: Operating expenses outlook - SG&A expenses are expected to rise in FY 2026 as investments are needed for growth [43] Question: Impact of the Tampa facility closure on gross margin - Some gross margin improvement is expected from the Tampa closure, but pressures from tariffs remain [67]